NCT03756311 2026-01-23
Expanded Access to NanoPac
NanOlogy, LLC
No longer available
Clinical Trials
12 trialsNCT04060628 2026-01-23
Expanded Access to NanoDoce
NanOlogy, LLC
No longer available
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04314895 2025-05-23
Trial of NanoPac Intratumoral Injection in Lung Cancer
NanOlogy, LLC
Phase 2 Completed
NCT02751528 2025-01-13
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
Phase 1 Terminated
NCT04727138 2022-05-16
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Exscientia AI Limited
Phase 1 Completed
NCT04221828 2022-03-29
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Phase 2 Terminated
NCT04771390 2021-08-25
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Bayer
Phase 1 Completed
NCT04260360 2020-08-04
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
Phase 1 Withdrawn
NCT01697020 2013-12-02
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
Nova Laboratories Limited
Phase 1 Completed